The Board of Directors of iX Biopharma Ltd. announced the appointment of Mr. Teo Woon Keng John as an Independent Non-Executive Director of the Company and as a member of the Audit Committee, Nominating Committee and Remuneration Committee of the Company with effect from 7 November 2022. The Board considers Mr. Teo Woon Keng John to be independent for the purposes of Catalist Rule 704(7) of the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist. Following the appointment of Mr. Teo Woon Keng John, the Board will be re-constituted as follows: Board of Directors: Eddy Lee Yip Hang: Executive Chairman and Chief Executive Officer; Albert Ho Shing Tung: Non-Independent Non-Executive Director; Patrick Donald Davies: Lead Independent Director; Angeline Tham Xiwen: Independent Non-Executive Director; Teo Woon Keng John: Independent Non-Executive Director.

The Nominating Committee and the Board shall deliberate on the reconstitution of the Board Committees of the Company (namely, Audit Committee, Nominating Committee, Remuneration Committee and Risk Management Committee. The Board will make the necessary announcement to update shareholders on the same in due course.